Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleoporin 210 pseudogene 2 (NUP210P2) is classified as a pseudogene, meaning it is a genomic DNA sequence similar to a functional gene (in this case, NUP210) but does not encode an active protein. Pseudogenes typically arise from duplication or retrotransposition events and accumulate mutations that prevent them from producing a functional product. As such, NUP210P2 does not serve as a therapeutic or druggable molecular target and has no known biological functions, disease associations, or clinical relevance[5]. Functional NUP210 (Nucleoporin 210, also called gp210) is a well-characterized component of the nuclear pore complex, with roles in nuclear envelope assembly and some autoimmune and cancer relevance[2][3][1]. However, NUP210P2 is distinct and non-functional. No aliases or biological functions are listed in the major gene databases for NUP210P2[5]. The apparent confusion can arise because pseudogenes are often named similarly to their functional counterparts, but should not be considered targets for pharmacological or biological intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleoporin 210 pseudogene 2 (NUP210P2).